FDA Approved: LETAIRIS — Supplemental Application (Gilead Sciences, Inc.)

View source ↗

Summary

FDA approves a supplemental application for LETAIRIS (ambrisentan) filed by Gilead Sciences, Inc., authorizing a change to its labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Arterial Hypertension

Drugs mentioned

• LETAIRIS (ambrisentan)

Snippet

SUPPL AP for LETAIRIS (AMBRISENTAN)